Genetic Technologies Limited (GENE) Cash Flow Statement
Where GENE’s cash came from and went, FY2024
June 30, 2024 · Australian dollars- Cash from operations
- −A$9.7M
- Capital expenditures
- A$32,967 0.4% of revenue
- Free cash flow
- −A$9.7M −126.7% margin
- Returned to shareholders
- —
- Change in cash
- −A$6.8M cash at year-end A$1.0M
Cash from operations
−A$9.7M
Investments (net)
+A$114,900
Shares issued
+A$2.6M
Other financing
+A$245,246
Currency & other
−A$88,834
Change in cash
−A$6.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GENE operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
GENE cash flow trends, FY2015–FY2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −A$9.7MFY2015 | −A$9.7MFY2024 | — | |
| Capital expenditures | A$192,592FY2015 | A$32,967FY2024 | −17.8%/yr | |
| Free cash flow | −A$9.9MFY2015 | −A$9.7MFY2024 | — | |
| Free cash flow margin | −491.3%FY2015 | −126.7%FY2024 | +364.6 pts | |
| Stock-based compensation | A$303,522FY2015 | A$124,177FY2024 | −9.5%/yr | |
| Dividends paid | A$0FY2015 | A$0FY2024 | — | |
| Share buybacks (net) | A$0FY2015 | A$0FY2019 | — | |
| Capex / revenue | 9.6%FY2015 | 0.4%FY2024 | −9.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GENE cash flow by activity
OperatingInvestingFinancingChange in cash
GENE net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GENE cash flow statement in Australian dollars
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −A$12.0M | −A$11.8M | −A$7.1M | −A$7.1M | −A$6.3M | −A$6.4M | −A$5.5M | −A$8.4M | −A$8.5M | −A$8.8M |
| Depreciation & amortization | A$534,888 | A$676,583 | A$578,668 | A$478,222 | A$265,933 | A$158,616 | A$303,749 | A$371,611 | A$390,074 | A$232,203 |
| Stock-based compensation | A$124,177 | A$253,452 | A$437,508 | A$714,577 | −A$32,498 | A$335,102 | A$129,635 | A$121,269 | A$50,239 | A$303,522 |
| Change in working capital | A$275,456 | A$328,470 | −A$2.2M | −A$270,508 | −A$30,113 | −A$490,241 | A$121,917 | A$204,501 | A$84,178 | A$152,348 |
| Other non-cash items | A$1.4M | A$769,323 | A$2.7M | −A$140,601 | A$379,355 | A$348,945 | −A$727,962 | A$892,806 | A$207,636 | −A$1.6M |
| Cash from operating activities | −A$9.7M | −A$9.7M | −A$5.7M | −A$6.3M | −A$5.7M | −A$6.1M | −A$5.6M | −A$6.8M | −A$7.7M | −A$9.7M |
| Investing activities | ||||||||||
| Capital expenditures | −A$32,967 | −A$17,552 | −A$96,794 | −A$642,000 | −A$38,100 | −A$50,309 | −A$2,385 | −A$234,799 | −A$303,462 | −A$192,592 |
| Investments (net) | A$114,900 | −A$503,000 | −A$3.5M | −A$642,000 | A$64,787 | −A$524,460 | −A$2,385 | −A$182,149 | −A$296,331 | A$0 |
| Acquisitions & other investing | A$32,967 | A$208,615 | A$96,794 | A$642,000 | A$38,100 | A$50,309 | A$17,603 | A$273,564 | A$303,462 | A$2.2M |
| Cash from investing activities | A$114,900 | −A$311,937 | −A$3.5M | −A$642,000 | A$64,787 | −A$524,460 | A$12,833 | −A$143,384 | −A$296,331 | A$2.0M |
| Financing activities | ||||||||||
| Dividends paid | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Share repurchases & issuance (net) | — | — | — | — | — | A$197,187 | A$0 | A$0 | A$0 | A$0 |
| Net borrowing (repayment) | — | −A$336,396 | −A$268,590 | −A$236,893 | −A$131,655 | −A$131,655 | −A$131,655 | −A$131,655 | A$0 | A$759,061 |
| Shares issued | A$2.6M | A$7.2M | A$8.5M | A$15.9M | A$21.8M | A$3.6M | A$0 | A$0 | A$0 | A$0 |
| Other financing | A$245,246 | −A$916,060 | −A$8.5M | −A$1.7M | −A$3.3M | −A$496,879 | A$121,692 | A$7.2M | −A$1,654 | A$22.1M |
| Cash from financing activities | A$2.8M | A$5.9M | −A$279,064 | A$13.9M | A$18.4M | A$3.1M | −A$9,963 | A$7.1M | −A$1,654 | A$22.9M |
| Summary | ||||||||||
| Net change in cash | −A$6.8M | −A$3.9M | A$21.4M | A$6.7M | A$12.1M | −A$3.4M | −A$5.5M | −A$191,432 | −A$7.2M | A$15.5M |
| Cash at end of period | A$1.0M | A$7.9M | A$11.7M | A$20.9M | A$14.2M | A$2.1M | A$5.5M | A$11.0M | A$11.2M | A$18.3M |
| Free cash flow | −A$9.7M | −A$9.7M | −A$5.8M | −A$6.9M | −A$5.8M | −A$6.1M | −A$5.6M | −A$7.0M | −A$8.0M | −A$9.9M |
| Free cash flow margin | −126.7% | −94.1% | −84.7% | −5,755.0% | −58,294.8% | −24,066.5% | −2,979.6% | −1,359.4% | −973.9% | −491.3% |
| Capex / revenue | 0.4% | 0.2% | 1.4% | 532.5% | 386.3% | 197.7% | 1.3% | 45.3% | 36.8% | 9.6% |
| Jun '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||||
| Net income | −A$5.6M | −A$6.4M | −A$3.2M | −A$4.2M | −A$3.1M | −A$5.5M | −A$2.7M | −A$3.2M | −A$1.6M | −A$3.9M | −A$1.9M |
| Depreciation & amortization | A$254,222 | A$280,665 | A$140,334 | A$348,371 | A$173,198 | A$330,187 | A$165,094 | A$348,527 | A$148,682 | A$216,765 | A$140,652 |
| Stock-based compensation | A$124,177 | — | — | A$253,452 | A$126,727 | — | — | A$437,508 | A$218,754 | — | — |
| Change in working capital | −A$31,389 | — | — | A$164,236 | A$164,236 | — | — | −A$2.2M | −A$1.0M | — | — |
| Other non-cash items | −A$416,328 | A$2.2M | A$1.1M | −A$107,675 | A$1.7M | A$2.4M | −A$500,859 | A$3.2M | A$1.5M | −A$458,687 | −A$268,357 |
| Cash from operating activities | −A$5.7M | −A$3.9M | −A$2.0M | −A$3.6M | −A$1.0M | −A$2.7M | −A$3.1M | −A$1.5M | −A$761,336 | −A$4.1M | −A$2.1M |
| Investing activities | |||||||||||
| Capital expenditures | −A$4,728 | −A$7,000 | −A$21,000 | −A$14,439 | −A$1,000 | −A$114 | −A$3,000 | −A$79,794 | −A$8,317 | −A$25,000 | −A$2,000 |
| Investments (net) | — | −A$7,000 | −A$21,000 | −A$12,000 | −A$1,000 | −A$1,000 | −A$489,000 | A$27,837 | A$0 | −A$25,000 | −A$3.5M |
| Acquisitions & other investing | A$29,645 | A$7,000 | — | A$205,502 | A$50,808 | A$80,560 | A$287,223 | A$79,794 | −A$6,385 | A$25,000 | A$1.8M |
| Cash from investing activities | A$24,917 | −A$7,000 | — | A$179,063 | A$48,808 | A$79,446 | −A$204,777 | A$27,837 | −A$14,702 | −A$25,000 | −A$1.7M |
| Financing activities | |||||||||||
| Dividends paid | — | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | — | — | — |
| Net borrowing (repayment) | — | — | — | −A$84,956 | −A$84,956 | −A$83,242 | −A$83,242 | −A$126,572 | −A$126,572 | −A$7,723 | −A$7,723 |
| Shares issued | A$0 | A$0 | A$0 | A$399 | A$7.2M | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Other financing | A$3.0M | −A$172,851 | −A$87,541 | −A$315,500 | −A$767,044 | −A$83,242 | A$0 | −A$137,047 | −A$5,237 | −A$23,711 | A$0 |
| Cash from financing activities | A$3.0M | −A$172,851 | −A$87,541 | −A$400,057 | A$6.3M | −A$166,484 | −A$83,242 | −A$263,619 | −A$131,809 | −A$31,434 | −A$7,723 |
| Summary | |||||||||||
| Net change in cash | −A$3.7M | −A$1.2M | −A$3.0M | −A$2.6M | A$5.4M | −A$2.9M | −A$3.8M | A$383,000 | A$13.4M | −A$2.2M | −A$5.2M |
| Cash at end of period | A$681,613 | A$3.7M | A$4.9M | A$7.9M | A$10.5M | A$5.0M | A$7.9M | A$11.7M | A$11.3M | A$13.5M | A$15.7M |
| Free cash flow | −A$5.7M | −A$3.9M | −A$21,000 | −A$2.5M | −A$1.0M | −A$2.7M | −A$3,000 | −A$1.6M | −A$769,653 | −A$4.1M | −A$2,000 |
| Free cash flow margin | −118.2% | −98.6% | −0.9% | −54.9% | −38.4% | −65.6% | −0.1% | −27.4% | −26.7% | −120.1% | −0.1% |
| Capex / revenue | 0.1% | 0.2% | 0.9% | 0.3% | 0.0% | 0.0% | 0.1% | 1.4% | 0.3% | 0.7% | 0.1% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported; data from EODHD.
GENE cash generation
In fiscal 2024 (ended June 30, 2024), Genetic Technologies generated -A$9.7 million of cash from operations and spent A$0.0 million on capital expenditures, leaving free cash flow of -A$9.7 million, −126.7% of revenue. Cash and equivalents fell by A$6.8 million over the year.
Related: GENE income statement, GENE balance sheet. See the GENE stock overview for the latest quote and news.
GENE cash flow FAQ
What is Genetic Technologies's free cash flow?
Genetic Technologies's free cash flow was -A$9.7 million in fiscal 2024: -A$9.7 million of operating cash flow minus A$0.0 million of capital expenditures It was -A$9.7 million a year earlier..
How much cash does Genetic Technologies generate from operations?
Genetic Technologies generated -A$9.7 million of cash from operating activities in fiscal 2024.
How much does Genetic Technologies spend on capital expenditures?
Genetic Technologies spent A$0.0 million on capital expenditures in fiscal 2024, 0.4% of revenue, compared with A$0.0 million the year before.